MedPath

Midomafetamine

Generic Name
Midomafetamine
Drug Type
Small Molecule
Chemical Formula
C11H15NO2
CAS Number
42542-10-9
Unique Ingredient Identifier
KE1SEN21RM
Background

An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

Indication

Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.

Clinical Trials
Related News

-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms

Phase 1
Completed
Conditions
Metabolism
Interaction
Interventions
First Posted Date
2011-10-06
Last Posted Date
2011-10-06
Lead Sponsor
Parc de Salut Mar
Target Recruit Count
27
Registration Number
NCT01447472
Locations
🇪🇸

IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar), Barcelona, Spain

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

Phase 1
Completed
Conditions
Psychological Effects of Study Drug
Interventions
First Posted Date
2011-07-28
Last Posted Date
2024-10-31
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
107
Registration Number
NCT01404754
Locations
🇺🇸

Santa Fe MDMA Therapy Training, LLC, Santa Fe, New Mexico, United States

🇺🇸

Aguazul Bluewater, Inc., Boulder, Colorado, United States

🇺🇸

Zen Therapeutic Solutions, Mount Pleasant, South Carolina, United States

Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)

Phase 1
Completed
Conditions
Substance-Related Disorders
Mood Disorder
Amphetamine-Related Disorders
Interventions
Drug: placebo
First Posted Date
2011-06-30
Last Posted Date
2018-12-11
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
16
Registration Number
NCT01386177
Locations
🇨🇭

University Hospital Basel, Basel, Switzerland

Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)

Not Applicable
Completed
Conditions
Mood Disorder
Substance-Related Disorders
Amphetamine-Related Disorders
Interventions
Drug: placebo
First Posted Date
2011-01-05
Last Posted Date
2018-12-11
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
16
Registration Number
NCT01270672
Locations
🇨🇭

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Neurobiology and Pharmacokinets of Acute MDMA Administration

Phase 1
Completed
Conditions
Substance-Related Disorders
First Posted Date
2010-06-22
Last Posted Date
2019-12-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
187
Registration Number
NCT01148342
Locations
🇺🇸

National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States

Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)

Phase 1
Completed
Conditions
Mood Disorder
Substance-Related Disorders
Amphetamine-Related Disorders
Interventions
Drug: placebo
First Posted Date
2010-06-03
Last Posted Date
2013-01-25
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
16
Registration Number
NCT01136278
Locations
🇨🇭

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

Not Applicable
Completed
Conditions
MDMA Discontinuation Syndrome
Interventions
First Posted Date
2010-01-21
Last Posted Date
2013-05-31
Lead Sponsor
California Pacific Medical Center Research Institute
Target Recruit Count
12
Registration Number
NCT01053403
Locations
🇺🇸

CPMC Addiction & Pharmacology Research Laboratory (APRL), San Francisco, California, United States

Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)

Phase 1
Completed
Conditions
Mood Disorder
Substance-Related Disorders
Amphetamine-Related Disorders
Interventions
Drug: Placebo
First Posted Date
2009-10-06
Last Posted Date
2013-01-25
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
16
Registration Number
NCT00990067
Locations
🇨🇭

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

Phase 1
Completed
Conditions
Mood Disorder
Substance-Related Disorders
Amphetamine-Related Disorders
Interventions
First Posted Date
2009-05-08
Last Posted Date
2009-06-15
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
16
Registration Number
NCT00895804
Locations
🇨🇭

Heffter Research Center, University Hospital of Psychiatry, Zurich, Switzerland

Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

Phase 1
Completed
Conditions
Mood Disorder
Substance-related Disorders
Amphetamine-related Disorders
Interventions
Drug: Reboxetine, 8 mg
Drug: Placebo
First Posted Date
2009-04-23
Last Posted Date
2013-01-25
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
16
Registration Number
NCT00886886
Locations
🇨🇭

University Hospital, Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy